EXEL vs GILD
Exelixis, Inc. and Gilead Sciences, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | EXEL | GILD |
|---|---|---|
| Revenue | $2.3B | $29.4B |
| Net income | $782.6M | $8.5B |
| Gross margin | 96.4% | 78.8% |
| Net margin | 33.7% | 28.9% |
| Return on equity | 35.5% | 40.5% |
| Diluted EPS | $2.78 | $6.78 |
| Dividend / share | — | $3.16 |
| Payout ratio | — | 47.0% |
| Free cash flow | $875.8M | $9.5B |
| Equity | $2.2B | $22.7B |
| Net debt / equity | −0.66× | 0.77× |
| Current ratio | 3.56× | 1.55× |
| Revenue CAGR 5y | 18.6% | 3.6% |
| Profit CAGR 5y | 47.6% | 133.3% |
GILD bills 12.7× the revenue of EXEL, and EXEL keeps more of each dollar of revenue as profit (33.7% against 28.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | EXEL | GILD |
|---|---|---|
| FY2025 | $2.3B | $29.4B |
| FY2024 | $2.2B | $28.8B |
| FY2023 | $1.8B | $27.1B |
| FY2022 | $1.6B | $27.3B |
| FY2021 | $1.4B | $27.3B |
| FY2020 | $987.5M | $24.7B |
| FY2019 | $967.8M | $22.4B |
| FY2018 | $853.8M | $22.1B |
| FY2017 | $452.5M | $26.1B |
| FY2016 | $191.5M | $30.4B |
Net income by year
Bottom line
| Fiscal year | EXEL | GILD |
|---|---|---|
| FY2025 | $782.6M | $8.5B |
| FY2024 | $521.3M | $480.0M |
| FY2023 | $207.8M | $5.7B |
| FY2022 | $182.3M | $4.6B |
| FY2021 | $231.1M | $6.2B |
| FY2020 | $111.8M | $123.0M |
| FY2019 | $321.0M | $5.4B |
| FY2018 | $690.1M | $5.5B |
| FY2017 | $154.2M | $4.6B |
| FY2016 | $-70.2M | $13.5B |
Advertisement
AdSense · Rectangle 336×280
More in this industry